1. Academic Validation
  2. A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/ MAPK mediated apoptosis

A novel mechanism of 6-methoxydihydroavicine in suppressing ovarian carcinoma by disrupting mitochondrial homeostasis and triggering ROS/ MAPK mediated apoptosis

  • Front Pharmacol. 2023 May 5:14:1093650. doi: 10.3389/fphar.2023.1093650.
Huachang Zhang 1 Fugen Shangguan 2 Lan Zhang 3 Nengfang Ma 4 Shuling Song 5 Li Ma 1 Chuntong Liu 1 Mengke Liu 1 Jing An 6 Hua Li 3 Qizhi Cao 1
Affiliations

Affiliations

  • 1 Department of Immunology, School of Basic Medical Sciences, Binzhou Medical University, Yantai, Shandong, China.
  • 2 Key Laboratory of Diagnosis and Treatment of Severe Hepato-Pancreatic Diseases of Zhejiang Province, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
  • 3 The Affiliated Taian City Central Hospital of Qingdao University, Taian, Shandong, China.
  • 4 School of Life and Environmental Sciences, Wenzhou University, Wenzhou, China.
  • 5 School of Gerontology, Binzhou Medical University, Yantai, Shandong, China.
  • 6 Division of Infectious Diseases and Global Health, School of Medicine, University of California San Diego (UCSD), La Jolla, CA, United States.
Abstract

Introduction: Alkaloids derived from M. cordata (Papaveraceae family), have been found to display antineoplastic activity in several types of Cancer. However, the antitumor effects and mechanisms of a new alkaloid extracted from the fruits of M. cordata, named 6-Methoxydihydroavicine (6-ME), remains unclear in the case of ovarian Cancer (OC). Methods: CCK-8 assay was employed to analyze the cell viabilities of OC cells. RTCA, and colony-formation assays were performed to measure OC cell growth. Alterations in Apoptosis and ROS levels were detected by flow cytometry in accordance with the instructions of corresponding assay kits. A Seahorse XFe96 was executed conducted to confirm the effects of 6-ME on cellular bioenergetics. Western blot and q-RT-PCR were conducted to detect alterations in target proteins. The subcutaneous xenografted tumor model of OC was used to further validate the anti-tumor activity of 6-ME in vivo. Results: Here, we reported for the first time that 6-ME inhibits OC cells growth in vitro and in vivo. Meanwhile, we found that 6-ME showed great antineoplastic activities by disrupting mitochondria homeostasis and promoting Apoptosis in OC cells. Further investigation of the upstream signaling of Apoptosis revealed that 6-ME-triggered Apoptosis was induced by Reactive Oxygen Species (ROS)-mediated mitogen-activated protein kinase (MAPK) activation and mitochondria dysfunction in OC cells. Furthermore, we found oxaloacetic acid (OAA), a crucial metabolite has been proved to be related to NADPH production, can block the cytotoxicity and accumulation of ROS caused by 6-ME in OC cells. Discussion: In summary, our data show that 6-ME exhibits cytotoxicity to OC cells in a ROS-dependent manner by interrupting mitochondrial respiration homeostasis and inducing MAPK-mediated Apoptosis. This evidence suggests that 6-ME is a promising remedy for OC intervention.

Keywords

6-methoxydihydroavicine (6-ME); MAPK; mitochondria homeostasis; ovarian cancer (OC); oxaloacetic acid (OAA) metabolism; reactive oxygen species (ROS).

Figures